Acceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher and Provide Overview of ACE-083 Phase 2 Trial

Webcast to be held October 28, 2016 at 10:00 a.m. EDT

CAMBRIDGE, Mass.--()--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that it will host an educational webinar on facioscapulohumeral muscular dystrophy (FSHD) and the Company’s Phase 2 clinical trial of ACE-083 in FSHD patients. The webinar will be led by neuromuscular disease expert, Jeffrey Statland, M.D., M.P.H., and Acceleron management, at 10:00 a.m. EDT on Friday, October 28, 2016.

Dr. Statland is an assistant professor of neurology at the University of Kansas Medical Center with both clinical and research training in neuromuscular diseases. His primary research interest is in FSHD, one of the most prevalent forms of muscular dystrophy, characterized by a progressive loss of muscle strength. During the webinar, Dr. Statland will provide an overview of FSHD, its clinical manifestations and unmet medical need. Acceleron management will provide an overview of ACE-083 and the design of the upcoming Phase 2 clinical trial. At the end of the presentation, Dr. Statland and Acceleron management will be available to answer questions from the call participants.

Conference Call and Webcast Details

Date:               Friday, October 28, 2016
Time: 10:00 a.m. (EDT)

Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the Acceleron FSHD Call.

The live webcast can be accessed on the Investors page of the Company's website at

A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About ACE-083

ACE-083 is a therapeutic candidate that acts as a ligand trap for members in the transforming growth factor-beta (TGF-β) superfamily involved in the regulation of muscle mass and strength. ACE-083 has been designed to increase muscle mass and strength selectively in the muscles into which the drug is administered. Acceleron is developing ACE-083 for diseases in which improved muscle strength in a specific set of muscles may provide a clinical benefit, such as facioscapulohumeral muscular dystrophy.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit Follow Acceleron on social media: @AcceleronPharma and LinkedIn.


Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
BMC Communications
Brad Miles, 646-513-3125

Recent Stories

RSS feed for Acceleron Pharma

Acceleron Pharma